ARF1 and liver cancer: To investigate the anti‐tumor effect of the new Arf1 inhibitors on human tumors, we seeded mouse livers with fresh human liver tumor samples and generated liver cancer patient‐derived xenografts (PDXs) in humanized HSC‐NCG mice (Figure 2j), which retained the major characteristics of the original human tumors and tumor immune microenvironment.